Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212178 | 0.81 | KMT2A (0.61) | SMN1; SMN2CYP19A1KMT2ACYP3A4POLB | |
| SCHEMBL24211766 | 0.80 | MTNR1A (0.54) | SMN1; SMN2TAAR1KMT2AMAPT | |
| SCHEMBL24211771 | 0.78 | AKR1B1 (0.46) | KMT2ACYP3A4POLBATMMAPT | |
| SCHEMBL24211769 | 0.73 | PTGS1 (0.55) | SMN1; SMN2KMT2APOLBATMMAPT | |
| SCHEMBL20630756 | 0.72 | HTR2A (0.73) | SMN1; SMN2HTR2ACYP19A1TAAR1KMT2A | |
| SCHEMBL24211782 | 0.71 | ALDH1A1 (0.57) | CYP19A1KMT2APOLBATMMAPT | |
| SCHEMBL23996020 | 0.69 | CHRM2 (0.59) | TAAR1POLB | |
| SCHEMBL1253319 | 0.68 | TAAR1 (0.77) | HTR2ACYP19A1TAAR1HTR2C | |
| SCHEMBL29364056 | 0.68 | TAAR1 (0.77) | HTR2ACYP19A1TAAR1HTR2C | |
| SCHEMBL10310312 | 0.67 | ADRA1A (0.58) | HTR2ATAAR1HTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | PCNA, POLM, MUS81 | SMN1; SMN2 4332/4885HTR2A 4198/4885CYP19A1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.